VintaBio will be at #ASGCT2024 next week to discuss making AAV and LVV gene therapy accessible using our expertise in manufacturing. Our technical team will be at Booth 1849 to discuss or schedule a meeting with us in the partnering portal. See you in Baltimore!
VintaBio
Biotechnology Research
Philadelphia, Pennsylvania 2,482 followers
VintaBio delivers customized process development and GMP manufacturing service for cell and gene therapy.
About us
VintaBio’s development and manufacturing team has over a century of experience in the cell and gene therapy space and its members have played key roles in the development of the most advanced therapies on the market today. Located in the historic Navy Yards of Philadelphia – the epicenter of cell and gene therapy innovation – VintaBio specializes in developing and manufacturing consistent, high-quality viral vectors, a vital and currently underserved area of CGT development. The company was founded by Junwei Sun and Dr. Shangzhen Zhou, who led development of the AAV vectors behind the first two FDA-approved gene therapies, as well as the lentiviral vector for the first FDA-approved cell therapy. VintaBio has raised $64 million in venture funding, which has been used to develop a brand new 22,500 square foot facility in Philadelphia created specifically to facilitate efficient cell and gene therapy manufacturing.
- Website
-
http://www.vintabio.com
External link for VintaBio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Philadelphia, Pennsylvania
- Type
- Privately Held
- Founded
- 2020
- Specialties
- Gene Therapy and Viral Vectors
Locations
-
Primary
Get directions
4050 S 26th St
Philadelphia, Pennsylvania 19112, US
Employees at VintaBio
-
Joseph Tyska, P.E, C.R.L
Director of Facilities, VintaBio, Philadelphia, PA
-
Lauren Cesarano
Microbiology Manager
-
Jieyan Pan
Senior Process Development Specialist at VintaBio
-
Matthew Ercolino
CGT team leader with broad upstream and downstream experience developing AAV and LV processes.
Updates
-
VintaBio is looking forward to #ASGCT2024 in Baltimore. Stop by Booth#1849 for a discussion on AAV and LVV manufacturing.
-
-
“One of the top challenges in bringing life-saving and life-changing cell and gene therapies to patients is the availability of a skilled workforce to research, develop, manufacture, and deploy these therapies,” said David Radspinner, CEO of VintaBio. “I am excited that VintaBio can collaborate with other top industry leaders through the Keystone LifeSci Collaborative. We will work together to address this workforce challenge and other shared business priorities, which in turn will help us achieve our company’s mission to accelerate our therapies through the clinic to patients, and to improve patient access through simplified and cost-effective manufacturing.” To learn more or to join the Keystone LifeSci Collaborative: https://lnkd.in/exTdgP8q
-
-
We're #hiring a new Controller in Philadelphia, Pennsylvania. Apply today or share this post with your network.
-
Making viral vectors accessible for gene therapy patients requires that timelines are met with high quality AAV & LVV. Lucia Fernandez, VP of Manufacturing & Technology of VintaBio, will be speaking on Thursday March 28, 2024 at 1:45PM at the 7th Annual Gene Therapy for Rare Disorders Conference in Boston, MA. #GTxRD #Genetherapy #raredisease
-
-
We're #hiring a new QA Operations Manager in Philadelphia, Pennsylvania. Apply today or share this post with your network.
-
We're #hiring a new QA Document Control & Training Specialist/Manager in Philadelphia, Pennsylvania. Apply today or share this post with your network.
-
We're #hiring a new Operations Engineer in Philadelphia, Pennsylvania. Apply today or share this post with your network.
-
Making viral vectors accessible for gene therapy patients requires that timelines are met with high quality AAV & LVV. Lucia Fernandez, VP of Manufacturing & Technology of VintaBio will be speaking on Thursday March 28, 2024 at 1:45PM at the 7th Annual Gene Therapy for Rare Disorders Conference in Boston, MA. #GTxRD #Genetherapy #raredisease
-
-
VintaBio makes viral vectors accessible for rare disease patients. The VintaProcess™ uses a scalable Viral Vector manufacturing platform delivering high quality AAV & LVV with a COGs advantage in a small footprint. Reach out to David and Jennifer to schedule meetings to discuss how Vintabio can get your rare disease therapy to patients. #GTxRD #Genetherapy #raredisease
-